D

Dhg Pharmaceutical Joint-Stock Co
VN:DHG

Watchlist Manager
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Watchlist
Price: 106 900 VND 3.29%
Market Cap: 14T VND
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one DHG stock under the Base Case scenario is 103 144.07 VND. Compared to the current market price of 106 900 VND, Dhg Pharmaceutical Joint-Stock Co is Overvalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DHG Relative Value
Base Case
103 144.07 VND
Overvaluation 4%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

2.9
P/S
P/S
Price to Sales
2.9
vs History
36
vs Industry
42
Median 3Y
2.7
Median 5Y
2.8
Industry
2.4
Forward
2.6
More Details
18.5
P/E
P/E
Price to Earnings
18.5
vs History
9
vs Industry
28
Median 3Y
16.3
Median 5Y
15.7
Industry
20.3
Forward
15.1
More Details
10.6
P/OCF
P/OCF
Price to OCF
10.6
vs History
85
vs Industry
38
Median 3Y
15.4
Median 5Y
14.8
Industry
15.6
More Details
10.9
P/FCFE
P/FCFE
Price to FCFE
10.9
vs History
88
vs Industry
30
Median 3Y
23.1
Median 5Y
20.2
Industry
23.1
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
11
vs Industry
23
Median 3Y
3
Median 5Y
3.1
Industry
2
More Details
2.4
EV/S
EV/S
Enterprise Value to Sales
2.4
vs History
38
vs Industry
46
Median 3Y
2.3
Median 5Y
2.3
Industry
2.5
Forward
2.2
More Details
5.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.5
vs History
26
vs Industry
39
Median 3Y
5.2
Median 5Y
5.1
Industry
4.8
More Details
12.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.1
vs History
33
vs Industry
30
Median 3Y
11.4
Median 5Y
11.3
Industry
12.5
Forward
9.6
More Details
14.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.6
vs History
20
vs Industry
31
Median 3Y
13.5
Median 5Y
12.8
Industry
15.7
Forward
12.3
More Details
9
EV/OCF
EV/OCF
Enterprise Value to OCF
9
vs History
84
vs Industry
42
Median 3Y
12.7
Median 5Y
12.6
Industry
14.1
More Details
9.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.6
vs History
76
vs Industry
33
Median 3Y
14.7
Median 5Y
14.1
Industry
17.6
More Details
4
EV/IC
EV/IC
Enterprise Value to IC
4
vs History
49
vs Industry
21
Median 3Y
3.8
Median 5Y
4
Industry
1.8
More Details

Multiples Across Competitors

DHG Competitors Multiples
Dhg Pharmaceutical Joint-Stock Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
14T VND 2.9 18.5 12.1 14.6
US
Eli Lilly and Co
NYSE:LLY
712.2B USD 14.5 64.1 34.5 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.5B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 18.9 12.5 14.2
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
178.5B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
157.1B GBP 3.8 26.8 129.7 195.6
US
Merck & Co Inc
NYSE:MRK
196.3B USD 3.1 11.3 8.1 9.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.6B USD 2.1 16.6 7.2 10.1
P/E Multiple
Earnings Growth PEG
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average P/E: 23.9
18.5
10%
1.9
US
Eli Lilly and Co
NYSE:LLY
64.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.8
36%
0.7
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.6
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBITDA: 394.9
12.1
11%
1.1
US
Eli Lilly and Co
NYSE:LLY
34.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
129.7
9%
14.4
US
Merck & Co Inc
NYSE:MRK
8.1
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBIT: 1 698.2
14.6
12%
1.2
US
Eli Lilly and Co
NYSE:LLY
37.7
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
195.6
21%
9.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
DHG intrinsic value, competitors valuation, and company profile.
DCF Valuation
DHG stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DHG stock valuation using valuation multiples.
Wall Street Estimates
DHG price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DHG stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.